ArticleFrontiers in oncology2025
Transformation of T-lymphoblastic lymphoma into acute myeloid leukemia after recurrence: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the diagnosis and treatment of the condition of T-lymphoblastic lymphoma (T-LBL) transforming into acute myeloid leukemia (AML) following recurrence. Methods: We conducted a retrospective analysis of a patient admitted to the First Affiliated Hospital of Henan University of Science and Technology in July 2022 with recurrent T-LBL that progressed to AML. Clinical manifestations, genetic and histopathological findings, and treatment outcomes were evaluated, complemented by a literature review. Results: The patient, initially diagnosed with T-LBL, achieved complete remission (CR) after combination chemotherapy. Following treatment cessation, the disease recurred and transformed into AML. Conclusion: The transformation of T-LBL into AML is exceedingly rare, and the underlying mechanisms of lineage switch remain unclear. Venetoclax combined with chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) may improve prognosis in such cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.